Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Compugen Ltd (CGEN)

Compugen Ltd (CGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Dollars and Wallets - Holding Money Bunched in Fist
5 Growth Stocks Under $10 to Scoop Up Now Barchart - Tue Jan 23, 2:30PM CST

Investment in penny stocks can be a risky proposition. However, here are 5 stocks that could have major upside potential, according to Wall Street analysts.

CGEN : 1.9800 (+4.76%)
QCOM : 161.35 (+0.73%)
GSAT : 1.3000 (+3.17%)
BITF : 2.11 (+2.93%)
INDI : 5.21 (+1.96%)
KOS : 5.83 (-0.68%)
Compugen to Present at Single Cell Genomics 2023 Meeting PR Newswire - Tue Oct 3, 2023

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire - Thu Aug 31, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen Reports Second Quarter 2023 Results PR Newswire - Mon Aug 7, 2023

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and...

CGEN : 1.9800 (+4.76%)
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023 PR Newswire - Mon Jul 24, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party PR Newswire - Mon Jul 17, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study PR Newswire - Thu Jun 22, 2023

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

CGEN : 1.9800 (+4.76%)
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire - Tue Jun 13, 2023

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...

CGEN : 1.9800 (+4.76%)
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer PR Newswire - Mon Jun 5, 2023

COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate 22% (2/9)...

CGEN : 1.9800 (+4.76%)

Barchart Exclusives

Should You Buy This Beaten-Down AI Stock for Its 4% Dividend Yield? Barchart - Tue Apr 23, 6:30PM CDT
Sales of AI-enabled gadgets are expected to drive hardware sales over the next few years. PC maker HP looks like an AI play worth buying for its nearly 4% dividend yield and tepid valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot